checkAd
    Startseite > Aktien > Apogee Therapeutics > Nachrichten
    Apogee Therapeutics Aktie
    53,69
     
    USD
    +0,73 %
    +0,39 USD
    Letzter Kurs 19:40:32 Nasdaq
    53,50
     
    USD
    200 STK
    Geldkurs 19:41:29
    53,88
     
    USD
    100 STK
    Briefkurs 19:41:29
    ISIN: US03770N1019 · WKN: A3EM1H · SYM: APGE · USA

    Neueste Nachrichten

    Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
    15.05.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
    13.05.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
    06.05.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
    25.03.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
    12.03.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
    08.03.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
    05.03.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
    05.03.24 · globenewswire · Apogee Therapeutics
    Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc
    05.03.24 · globenewswire · Apogee Therapeutics
    Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
    04.03.24 · globenewswire · Apogee Therapeutics
    Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    02.01.24 · globenewswire · Apogee Therapeutics
    Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
    13.11.23 · globenewswire · Apogee Therapeutics